Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up – Here’s What Happened

01 Jun 2026, 14:56 by Sarita Garza · The Markets Daily

Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $34.16, but opened at $40.60. Edgewise Therapeutics shares last traded at $39.70, with a volume of 1,144,422 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on EWTX shares. HC Wainwright raised shares of Edgewise Therapeutics to a “strong-buy” rating in a report on Thursday, February 26th. Stifel Nicolaus set a $25.00 price target on Edgewise Therapeutics in a research report on Thursday, February 26th. Piper Sandler reiterated an “overweight” rating on shares of Edgewise Therapeutics in a research note on Monday, February 9th. JPMorgan Chase & Co. upped their target price on Edgewise Therapeutics from $34.00 to $45.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 17th. Finally, Truist Financial set a $52.00 target price on Edgewise Therapeutics in a report on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.67.

Get Our Latest Analysis on EWTX

Edgewise Therapeutics Stock Up 11.7%

The business’s 50-day simple moving average is $32.74 and its two-hundred day simple moving average is $28.69. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of -23.12 and a beta of 0.27.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.04. On average, analysts expect that Edgewise Therapeutics, Inc. will post -2.13 earnings per share for the current year.

Insider Transactions at Edgewise Therapeutics

In other news, CMO Joanne M. Donovan sold 50,000 shares of Edgewise Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $38.57, for a total value of $1,928,500.00. Following the sale, the chief marketing officer owned 4,367 shares in the company, valued at $168,435.19. This trade represents a 91.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 83,892 shares of company stock worth $3,018,216 over the last quarter. Company insiders own 21.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EWTX. Aberdeen Group plc lifted its stake in shares of Edgewise Therapeutics by 39.8% in the third quarter. Aberdeen Group plc now owns 619,878 shares of the company’s stock worth $10,054,000 after buying an additional 176,559 shares in the last quarter. SG Americas Securities LLC grew its stake in Edgewise Therapeutics by 797.9% during the 4th quarter. SG Americas Securities LLC now owns 88,723 shares of the company’s stock valued at $2,202,000 after acquiring an additional 78,842 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Edgewise Therapeutics during the 3rd quarter valued at about $929,000. HighVista Strategies LLC raised its holdings in Edgewise Therapeutics by 198.5% in the 3rd quarter. HighVista Strategies LLC now owns 208,101 shares of the company’s stock valued at $3,375,000 after acquiring an additional 138,378 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in Edgewise Therapeutics by 315.2% in the 3rd quarter. GSA Capital Partners LLP now owns 113,243 shares of the company’s stock worth $1,837,000 after purchasing an additional 85,967 shares in the last quarter.

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.